Global Therapeutic Monoclonal Antibodies Supply, Demand and Key Producers, 2023-2029
The global Therapeutic Monoclonal Antibodies market size is expected to reach $ 336740 million by 2029, rising at a market growth of 10.5% CAGR during the forecast period (2023-2029).
The Therapeutic Antibodies Drug Market is driven by the remarkable potential of therapeutic antibodies to treat a diverse array of diseases, from cancer and autoimmune disorders to infectious diseases. Monoclonal antibodies have gained prominence as highly targeted and effective therapeutic agents that can modulate the immune system, neutralize pathogens, and inhibit disease-associated proteins. As precision medicine and biopharmaceutical innovations continue to advance, the demand for therapeutic antibodies grows. Innovations in antibody design, engineering, and manufacturing technologies further contribute to market expansion. Nevertheless, a significant challenge for this market is the need to address high production costs, optimize therapeutic antibody development processes, and navigate complex regulatory pathways while ensuring accessibility and affordability for patients. Overcoming manufacturing complexities, managing research and development costs, and addressing regulatory standards are ongoing challenges. Additionally, the market faces competition from small molecules and other biologic therapies, necessitating continuous research and development efforts to unlock the full therapeutic potential of therapeutic antibodies. Striking a balance between providing safe, effective, and accessible therapeutic antibody drugs while addressing scientific and regulatory challenges is essential for the continued growth of the Therapeutic Antibodies Drug Market.
Monoclonal antibodies (MABs) are a type of targeted drug therapy. These drugs recognise and find specific proteins on cancer cells. There are many different MABs to treat cancer. They work in different ways to kill the cancer cell or stop it from growing.
This report studies the global Therapeutic Monoclonal Antibodies demand, key companies, and key regions.
This report is a detailed and comprehensive analysis of the world market for Therapeutic Monoclonal Antibodies, and provides market size (US$ million) and Year-over-Year (YoY) growth, considering 2022 as the base year. This report explores demand trends and competition, as well as details the characteristics of Therapeutic Monoclonal Antibodies that contribute to its increasing demand across many markets.
Highlights and key features of the study
Global Therapeutic Monoclonal Antibodies total market, 2018-2029, (USD Million)
Global Therapeutic Monoclonal Antibodies total market by region & country, CAGR, 2018-2029, (USD Million)
U.S. VS China: Therapeutic Monoclonal Antibodies total market, key domestic companies and share, (USD Million)
Global Therapeutic Monoclonal Antibodies revenue by player and market share 2018-2023, (USD Million)
Global Therapeutic Monoclonal Antibodies total market by Type, CAGR, 2018-2029, (USD Million)
Global Therapeutic Monoclonal Antibodies total market by Application, CAGR, 2018-2029, (USD Million).
This reports profiles major players in the global Therapeutic Monoclonal Antibodies market based on the following parameters – company overview, revenue, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include AbbVie, Johnson & Johnson, Novartis, Gilead Sciences, Roche, Bristol-Myers Squibb, Amgen, AstraZeneca and Merck & Co, etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the World Therapeutic Monoclonal Antibodies market.
Detailed Segmentation:
Each section contains quantitative market data including market by value (US$ Millions), by player, by regions, by Type, and by Application. Data is given for the years 2018-2029 by year with 2022 as the base year, 2023 as the estimate year, and 2024-2029 as the forecast year.
Global Therapeutic Monoclonal Antibodies Market, By Region:
1. How big is the global Therapeutic Monoclonal Antibodies market?
2. What is the demand of the global Therapeutic Monoclonal Antibodies market?
3. What is the year over year growth of the global Therapeutic Monoclonal Antibodies market?
4. What is the total value of the global Therapeutic Monoclonal Antibodies market?
5. Who are the major players in the global Therapeutic Monoclonal Antibodies market?
The Therapeutic Antibodies Drug Market is driven by the remarkable potential of therapeutic antibodies to treat a diverse array of diseases, from cancer and autoimmune disorders to infectious diseases. Monoclonal antibodies have gained prominence as highly targeted and effective therapeutic agents that can modulate the immune system, neutralize pathogens, and inhibit disease-associated proteins. As precision medicine and biopharmaceutical innovations continue to advance, the demand for therapeutic antibodies grows. Innovations in antibody design, engineering, and manufacturing technologies further contribute to market expansion. Nevertheless, a significant challenge for this market is the need to address high production costs, optimize therapeutic antibody development processes, and navigate complex regulatory pathways while ensuring accessibility and affordability for patients. Overcoming manufacturing complexities, managing research and development costs, and addressing regulatory standards are ongoing challenges. Additionally, the market faces competition from small molecules and other biologic therapies, necessitating continuous research and development efforts to unlock the full therapeutic potential of therapeutic antibodies. Striking a balance between providing safe, effective, and accessible therapeutic antibody drugs while addressing scientific and regulatory challenges is essential for the continued growth of the Therapeutic Antibodies Drug Market.
Monoclonal antibodies (MABs) are a type of targeted drug therapy. These drugs recognise and find specific proteins on cancer cells. There are many different MABs to treat cancer. They work in different ways to kill the cancer cell or stop it from growing.
This report studies the global Therapeutic Monoclonal Antibodies demand, key companies, and key regions.
This report is a detailed and comprehensive analysis of the world market for Therapeutic Monoclonal Antibodies, and provides market size (US$ million) and Year-over-Year (YoY) growth, considering 2022 as the base year. This report explores demand trends and competition, as well as details the characteristics of Therapeutic Monoclonal Antibodies that contribute to its increasing demand across many markets.
Highlights and key features of the study
Global Therapeutic Monoclonal Antibodies total market, 2018-2029, (USD Million)
Global Therapeutic Monoclonal Antibodies total market by region & country, CAGR, 2018-2029, (USD Million)
U.S. VS China: Therapeutic Monoclonal Antibodies total market, key domestic companies and share, (USD Million)
Global Therapeutic Monoclonal Antibodies revenue by player and market share 2018-2023, (USD Million)
Global Therapeutic Monoclonal Antibodies total market by Type, CAGR, 2018-2029, (USD Million)
Global Therapeutic Monoclonal Antibodies total market by Application, CAGR, 2018-2029, (USD Million).
This reports profiles major players in the global Therapeutic Monoclonal Antibodies market based on the following parameters – company overview, revenue, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include AbbVie, Johnson & Johnson, Novartis, Gilead Sciences, Roche, Bristol-Myers Squibb, Amgen, AstraZeneca and Merck & Co, etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the World Therapeutic Monoclonal Antibodies market.
Detailed Segmentation:
Each section contains quantitative market data including market by value (US$ Millions), by player, by regions, by Type, and by Application. Data is given for the years 2018-2029 by year with 2022 as the base year, 2023 as the estimate year, and 2024-2029 as the forecast year.
Global Therapeutic Monoclonal Antibodies Market, By Region:
- United States
- China
- Europe
- Japan
- South Korea
- ASEAN
- India
- Rest of World
- Mouse-derived Antibodies
- Chimeric Antibodies
- Humanized Antibodies
- Immune Diseases
- Cancer
- Other
- AbbVie
- Johnson & Johnson
- Novartis
- Gilead Sciences
- Roche
- Bristol-Myers Squibb
- Amgen
- AstraZeneca
- Merck & Co
- Takeda
- Merck KGaA
- Seagen
- Eli Lilly
- Ono Pharmaceutical
- Pfizer
- Regeneron
- Innovent
- Hengrui Medicine
1. How big is the global Therapeutic Monoclonal Antibodies market?
2. What is the demand of the global Therapeutic Monoclonal Antibodies market?
3. What is the year over year growth of the global Therapeutic Monoclonal Antibodies market?
4. What is the total value of the global Therapeutic Monoclonal Antibodies market?
5. Who are the major players in the global Therapeutic Monoclonal Antibodies market?
1 SUPPLY SUMMARY
1.1 Therapeutic Monoclonal Antibodies Introduction
1.2 World Therapeutic Monoclonal Antibodies Market Size & Forecast (2018 & 2022 & 2029)
1.3 World Therapeutic Monoclonal Antibodies Total Market by Region (by Headquarter Location)
1.3.1 World Therapeutic Monoclonal Antibodies Market Size by Region (2018-2029), (by Headquarter Location)
1.3.2 United States Therapeutic Monoclonal Antibodies Market Size (2018-2029)
1.3.3 China Therapeutic Monoclonal Antibodies Market Size (2018-2029)
1.3.4 Europe Therapeutic Monoclonal Antibodies Market Size (2018-2029)
1.3.5 Japan Therapeutic Monoclonal Antibodies Market Size (2018-2029)
1.3.6 South Korea Therapeutic Monoclonal Antibodies Market Size (2018-2029)
1.3.7 ASEAN Therapeutic Monoclonal Antibodies Market Size (2018-2029)
1.3.8 India Therapeutic Monoclonal Antibodies Market Size (2018-2029)
1.4 Market Drivers, Restraints and Trends
1.4.1 Therapeutic Monoclonal Antibodies Market Drivers
1.4.2 Factors Affecting Demand
1.4.3 Therapeutic Monoclonal Antibodies Major Market Trends
2 DEMAND SUMMARY
2.1 World Therapeutic Monoclonal Antibodies Consumption Value (2018-2029)
2.2 World Therapeutic Monoclonal Antibodies Consumption Value by Region
2.2.1 World Therapeutic Monoclonal Antibodies Consumption Value by Region (2018-2023)
2.2.2 World Therapeutic Monoclonal Antibodies Consumption Value Forecast by Region (2024-2029)
2.3 United States Therapeutic Monoclonal Antibodies Consumption Value (2018-2029)
2.4 China Therapeutic Monoclonal Antibodies Consumption Value (2018-2029)
2.5 Europe Therapeutic Monoclonal Antibodies Consumption Value (2018-2029)
2.6 Japan Therapeutic Monoclonal Antibodies Consumption Value (2018-2029)
2.7 South Korea Therapeutic Monoclonal Antibodies Consumption Value (2018-2029)
2.8 ASEAN Therapeutic Monoclonal Antibodies Consumption Value (2018-2029)
2.9 India Therapeutic Monoclonal Antibodies Consumption Value (2018-2029)
3 WORLD THERAPEUTIC MONOCLONAL ANTIBODIES COMPANIES COMPETITIVE ANALYSIS
3.1 World Therapeutic Monoclonal Antibodies Revenue by Player (2018-2023)
3.2 Industry Rank and Concentration Rate (CR)
3.2.1 Global Therapeutic Monoclonal Antibodies Industry Rank of Major Players
3.2.2 Global Concentration Ratios (CR4) for Therapeutic Monoclonal Antibodies in 2022
3.2.3 Global Concentration Ratios (CR8) for Therapeutic Monoclonal Antibodies in 2022
3.3 Therapeutic Monoclonal Antibodies Company Evaluation Quadrant
3.4 Therapeutic Monoclonal Antibodies Market: Overall Company Footprint Analysis
3.4.1 Therapeutic Monoclonal Antibodies Market: Region Footprint
3.4.2 Therapeutic Monoclonal Antibodies Market: Company Product Type Footprint
3.4.3 Therapeutic Monoclonal Antibodies Market: Company Product Application Footprint
3.5 Competitive Environment
3.5.1 Historical Structure of the Industry
3.5.2 Barriers of Market Entry
3.5.3 Factors of Competition
3.6 Mergers, Acquisitions Activity
4 UNITED STATES VS CHINA VS REST OF THE WORLD (BY HEADQUARTER LOCATION)
4.1 United States VS China: Therapeutic Monoclonal Antibodies Revenue Comparison (by Headquarter Location)
4.1.1 United States VS China: Therapeutic Monoclonal Antibodies Market Size Comparison (2018 & 2022 & 2029) (by Headquarter Location)
4.1.2 United States VS China: Therapeutic Monoclonal Antibodies Revenue Market Share Comparison (2018 & 2022 & 2029)
4.2 United States Based Companies VS China Based Companies: Therapeutic Monoclonal Antibodies Consumption Value Comparison
4.2.1 United States VS China: Therapeutic Monoclonal Antibodies Consumption Value Comparison (2018 & 2022 & 2029)
4.2.2 United States VS China: Therapeutic Monoclonal Antibodies Consumption Value Market Share Comparison (2018 & 2022 & 2029)
4.3 United States Based Therapeutic Monoclonal Antibodies Companies and Market Share, 2018-2023
4.3.1 United States Based Therapeutic Monoclonal Antibodies Companies, Headquarters (States, Country)
4.3.2 United States Based Companies Therapeutic Monoclonal Antibodies Revenue, (2018-2023)
4.4 China Based Companies Therapeutic Monoclonal Antibodies Revenue and Market Share, 2018-2023
4.4.1 China Based Therapeutic Monoclonal Antibodies Companies, Company Headquarters (Province, Country)
4.4.2 China Based Companies Therapeutic Monoclonal Antibodies Revenue, (2018-2023)
4.5 Rest of World Based Therapeutic Monoclonal Antibodies Companies and Market Share, 2018-2023
4.5.1 Rest of World Based Therapeutic Monoclonal Antibodies Companies, Headquarters (States, Country)
4.5.2 Rest of World Based Companies Therapeutic Monoclonal Antibodies Revenue, (2018-2023)
5 MARKET ANALYSIS BY TYPE
5.1 World Therapeutic Monoclonal Antibodies Market Size Overview by Type: 2018 VS 2022 VS 2029
5.2 Segment Introduction by Type
5.2.1 Mouse-derived Antibodies
5.2.2 Chimeric Antibodies
5.2.3 Humanized Antibodies
5.3 Market Segment by Type
5.3.1 World Therapeutic Monoclonal Antibodies Market Size by Type (2018-2023)
5.3.2 World Therapeutic Monoclonal Antibodies Market Size by Type (2024-2029)
5.3.3 World Therapeutic Monoclonal Antibodies Market Size Market Share by Type (2018-2029)
6 MARKET ANALYSIS BY APPLICATION
6.1 World Therapeutic Monoclonal Antibodies Market Size Overview by Application: 2018 VS 2022 VS 2029
6.2 Segment Introduction by Application
6.2.1 Immune Diseases
6.2.2 Cancer
6.2.3 Other
6.3 Market Segment by Application
6.3.1 World Therapeutic Monoclonal Antibodies Market Size by Application (2018-2023)
6.3.2 World Therapeutic Monoclonal Antibodies Market Size by Application (2024-2029)
6.3.3 World Therapeutic Monoclonal Antibodies Market Size by Application (2018-2029)
7 COMPANY PROFILES
7.1 AbbVie
7.1.1 AbbVie Details
7.1.2 AbbVie Major Business
7.1.3 AbbVie Therapeutic Monoclonal Antibodies Product and Services
7.1.4 AbbVie Therapeutic Monoclonal Antibodies Revenue, Gross Margin and Market Share (2018-2023)
7.1.5 AbbVie Recent Developments/Updates
7.1.6 AbbVie Competitive Strengths & Weaknesses
7.2 Johnson & Johnson
7.2.1 Johnson & Johnson Details
7.2.2 Johnson & Johnson Major Business
7.2.3 Johnson & Johnson Therapeutic Monoclonal Antibodies Product and Services
7.2.4 Johnson & Johnson Therapeutic Monoclonal Antibodies Revenue, Gross Margin and Market Share (2018-2023)
7.2.5 Johnson & Johnson Recent Developments/Updates
7.2.6 Johnson & Johnson Competitive Strengths & Weaknesses
7.3 Novartis
7.3.1 Novartis Details
7.3.2 Novartis Major Business
7.3.3 Novartis Therapeutic Monoclonal Antibodies Product and Services
7.3.4 Novartis Therapeutic Monoclonal Antibodies Revenue, Gross Margin and Market Share (2018-2023)
7.3.5 Novartis Recent Developments/Updates
7.3.6 Novartis Competitive Strengths & Weaknesses
7.4 Gilead Sciences
7.4.1 Gilead Sciences Details
7.4.2 Gilead Sciences Major Business
7.4.3 Gilead Sciences Therapeutic Monoclonal Antibodies Product and Services
7.4.4 Gilead Sciences Therapeutic Monoclonal Antibodies Revenue, Gross Margin and Market Share (2018-2023)
7.4.5 Gilead Sciences Recent Developments/Updates
7.4.6 Gilead Sciences Competitive Strengths & Weaknesses
7.5 Roche
7.5.1 Roche Details
7.5.2 Roche Major Business
7.5.3 Roche Therapeutic Monoclonal Antibodies Product and Services
7.5.4 Roche Therapeutic Monoclonal Antibodies Revenue, Gross Margin and Market Share (2018-2023)
7.5.5 Roche Recent Developments/Updates
7.5.6 Roche Competitive Strengths & Weaknesses
7.6 Bristol-Myers Squibb
7.6.1 Bristol-Myers Squibb Details
7.6.2 Bristol-Myers Squibb Major Business
7.6.3 Bristol-Myers Squibb Therapeutic Monoclonal Antibodies Product and Services
7.6.4 Bristol-Myers Squibb Therapeutic Monoclonal Antibodies Revenue, Gross Margin and Market Share (2018-2023)
7.6.5 Bristol-Myers Squibb Recent Developments/Updates
7.6.6 Bristol-Myers Squibb Competitive Strengths & Weaknesses
7.7 Amgen
7.7.1 Amgen Details
7.7.2 Amgen Major Business
7.7.3 Amgen Therapeutic Monoclonal Antibodies Product and Services
7.7.4 Amgen Therapeutic Monoclonal Antibodies Revenue, Gross Margin and Market Share (2018-2023)
7.7.5 Amgen Recent Developments/Updates
7.7.6 Amgen Competitive Strengths & Weaknesses
7.8 AstraZeneca
7.8.1 AstraZeneca Details
7.8.2 AstraZeneca Major Business
7.8.3 AstraZeneca Therapeutic Monoclonal Antibodies Product and Services
7.8.4 AstraZeneca Therapeutic Monoclonal Antibodies Revenue, Gross Margin and Market Share (2018-2023)
7.8.5 AstraZeneca Recent Developments/Updates
7.8.6 AstraZeneca Competitive Strengths & Weaknesses
7.9 Merck & Co
7.9.1 Merck & Co Details
7.9.2 Merck & Co Major Business
7.9.3 Merck & Co Therapeutic Monoclonal Antibodies Product and Services
7.9.4 Merck & Co Therapeutic Monoclonal Antibodies Revenue, Gross Margin and Market Share (2018-2023)
7.9.5 Merck & Co Recent Developments/Updates
7.9.6 Merck & Co Competitive Strengths & Weaknesses
7.10 Takeda
7.10.1 Takeda Details
7.10.2 Takeda Major Business
7.10.3 Takeda Therapeutic Monoclonal Antibodies Product and Services
7.10.4 Takeda Therapeutic Monoclonal Antibodies Revenue, Gross Margin and Market Share (2018-2023)
7.10.5 Takeda Recent Developments/Updates
7.10.6 Takeda Competitive Strengths & Weaknesses
7.11 Merck KGaA
7.11.1 Merck KGaA Details
7.11.2 Merck KGaA Major Business
7.11.3 Merck KGaA Therapeutic Monoclonal Antibodies Product and Services
7.11.4 Merck KGaA Therapeutic Monoclonal Antibodies Revenue, Gross Margin and Market Share (2018-2023)
7.11.5 Merck KGaA Recent Developments/Updates
7.11.6 Merck KGaA Competitive Strengths & Weaknesses
7.12 Seagen
7.12.1 Seagen Details
7.12.2 Seagen Major Business
7.12.3 Seagen Therapeutic Monoclonal Antibodies Product and Services
7.12.4 Seagen Therapeutic Monoclonal Antibodies Revenue, Gross Margin and Market Share (2018-2023)
7.12.5 Seagen Recent Developments/Updates
7.12.6 Seagen Competitive Strengths & Weaknesses
7.13 Eli Lilly
7.13.1 Eli Lilly Details
7.13.2 Eli Lilly Major Business
7.13.3 Eli Lilly Therapeutic Monoclonal Antibodies Product and Services
7.13.4 Eli Lilly Therapeutic Monoclonal Antibodies Revenue, Gross Margin and Market Share (2018-2023)
7.13.5 Eli Lilly Recent Developments/Updates
7.13.6 Eli Lilly Competitive Strengths & Weaknesses
7.14 Ono Pharmaceutical
7.14.1 Ono Pharmaceutical Details
7.14.2 Ono Pharmaceutical Major Business
7.14.3 Ono Pharmaceutical Therapeutic Monoclonal Antibodies Product and Services
7.14.4 Ono Pharmaceutical Therapeutic Monoclonal Antibodies Revenue, Gross Margin and Market Share (2018-2023)
7.14.5 Ono Pharmaceutical Recent Developments/Updates
7.14.6 Ono Pharmaceutical Competitive Strengths & Weaknesses
7.15 Pfizer
7.15.1 Pfizer Details
7.15.2 Pfizer Major Business
7.15.3 Pfizer Therapeutic Monoclonal Antibodies Product and Services
7.15.4 Pfizer Therapeutic Monoclonal Antibodies Revenue, Gross Margin and Market Share (2018-2023)
7.15.5 Pfizer Recent Developments/Updates
7.15.6 Pfizer Competitive Strengths & Weaknesses
7.16 Regeneron
7.16.1 Regeneron Details
7.16.2 Regeneron Major Business
7.16.3 Regeneron Therapeutic Monoclonal Antibodies Product and Services
7.16.4 Regeneron Therapeutic Monoclonal Antibodies Revenue, Gross Margin and Market Share (2018-2023)
7.16.5 Regeneron Recent Developments/Updates
7.16.6 Regeneron Competitive Strengths & Weaknesses
7.17 Innovent
7.17.1 Innovent Details
7.17.2 Innovent Major Business
7.17.3 Innovent Therapeutic Monoclonal Antibodies Product and Services
7.17.4 Innovent Therapeutic Monoclonal Antibodies Revenue, Gross Margin and Market Share (2018-2023)
7.17.5 Innovent Recent Developments/Updates
7.17.6 Innovent Competitive Strengths & Weaknesses
7.18 Hengrui Medicine
7.18.1 Hengrui Medicine Details
7.18.2 Hengrui Medicine Major Business
7.18.3 Hengrui Medicine Therapeutic Monoclonal Antibodies Product and Services
7.18.4 Hengrui Medicine Therapeutic Monoclonal Antibodies Revenue, Gross Margin and Market Share (2018-2023)
7.18.5 Hengrui Medicine Recent Developments/Updates
7.18.6 Hengrui Medicine Competitive Strengths & Weaknesses
8 INDUSTRY CHAIN ANALYSIS
8.1 Therapeutic Monoclonal Antibodies Industry Chain
8.2 Therapeutic Monoclonal Antibodies Upstream Analysis
8.3 Therapeutic Monoclonal Antibodies Midstream Analysis
8.4 Therapeutic Monoclonal Antibodies Downstream Analysis
9 RESEARCH FINDINGS AND CONCLUSION
10 APPENDIX
10.1 Methodology
10.2 Research Process and Data Source
10.3 Disclaimer
1.1 Therapeutic Monoclonal Antibodies Introduction
1.2 World Therapeutic Monoclonal Antibodies Market Size & Forecast (2018 & 2022 & 2029)
1.3 World Therapeutic Monoclonal Antibodies Total Market by Region (by Headquarter Location)
1.3.1 World Therapeutic Monoclonal Antibodies Market Size by Region (2018-2029), (by Headquarter Location)
1.3.2 United States Therapeutic Monoclonal Antibodies Market Size (2018-2029)
1.3.3 China Therapeutic Monoclonal Antibodies Market Size (2018-2029)
1.3.4 Europe Therapeutic Monoclonal Antibodies Market Size (2018-2029)
1.3.5 Japan Therapeutic Monoclonal Antibodies Market Size (2018-2029)
1.3.6 South Korea Therapeutic Monoclonal Antibodies Market Size (2018-2029)
1.3.7 ASEAN Therapeutic Monoclonal Antibodies Market Size (2018-2029)
1.3.8 India Therapeutic Monoclonal Antibodies Market Size (2018-2029)
1.4 Market Drivers, Restraints and Trends
1.4.1 Therapeutic Monoclonal Antibodies Market Drivers
1.4.2 Factors Affecting Demand
1.4.3 Therapeutic Monoclonal Antibodies Major Market Trends
2 DEMAND SUMMARY
2.1 World Therapeutic Monoclonal Antibodies Consumption Value (2018-2029)
2.2 World Therapeutic Monoclonal Antibodies Consumption Value by Region
2.2.1 World Therapeutic Monoclonal Antibodies Consumption Value by Region (2018-2023)
2.2.2 World Therapeutic Monoclonal Antibodies Consumption Value Forecast by Region (2024-2029)
2.3 United States Therapeutic Monoclonal Antibodies Consumption Value (2018-2029)
2.4 China Therapeutic Monoclonal Antibodies Consumption Value (2018-2029)
2.5 Europe Therapeutic Monoclonal Antibodies Consumption Value (2018-2029)
2.6 Japan Therapeutic Monoclonal Antibodies Consumption Value (2018-2029)
2.7 South Korea Therapeutic Monoclonal Antibodies Consumption Value (2018-2029)
2.8 ASEAN Therapeutic Monoclonal Antibodies Consumption Value (2018-2029)
2.9 India Therapeutic Monoclonal Antibodies Consumption Value (2018-2029)
3 WORLD THERAPEUTIC MONOCLONAL ANTIBODIES COMPANIES COMPETITIVE ANALYSIS
3.1 World Therapeutic Monoclonal Antibodies Revenue by Player (2018-2023)
3.2 Industry Rank and Concentration Rate (CR)
3.2.1 Global Therapeutic Monoclonal Antibodies Industry Rank of Major Players
3.2.2 Global Concentration Ratios (CR4) for Therapeutic Monoclonal Antibodies in 2022
3.2.3 Global Concentration Ratios (CR8) for Therapeutic Monoclonal Antibodies in 2022
3.3 Therapeutic Monoclonal Antibodies Company Evaluation Quadrant
3.4 Therapeutic Monoclonal Antibodies Market: Overall Company Footprint Analysis
3.4.1 Therapeutic Monoclonal Antibodies Market: Region Footprint
3.4.2 Therapeutic Monoclonal Antibodies Market: Company Product Type Footprint
3.4.3 Therapeutic Monoclonal Antibodies Market: Company Product Application Footprint
3.5 Competitive Environment
3.5.1 Historical Structure of the Industry
3.5.2 Barriers of Market Entry
3.5.3 Factors of Competition
3.6 Mergers, Acquisitions Activity
4 UNITED STATES VS CHINA VS REST OF THE WORLD (BY HEADQUARTER LOCATION)
4.1 United States VS China: Therapeutic Monoclonal Antibodies Revenue Comparison (by Headquarter Location)
4.1.1 United States VS China: Therapeutic Monoclonal Antibodies Market Size Comparison (2018 & 2022 & 2029) (by Headquarter Location)
4.1.2 United States VS China: Therapeutic Monoclonal Antibodies Revenue Market Share Comparison (2018 & 2022 & 2029)
4.2 United States Based Companies VS China Based Companies: Therapeutic Monoclonal Antibodies Consumption Value Comparison
4.2.1 United States VS China: Therapeutic Monoclonal Antibodies Consumption Value Comparison (2018 & 2022 & 2029)
4.2.2 United States VS China: Therapeutic Monoclonal Antibodies Consumption Value Market Share Comparison (2018 & 2022 & 2029)
4.3 United States Based Therapeutic Monoclonal Antibodies Companies and Market Share, 2018-2023
4.3.1 United States Based Therapeutic Monoclonal Antibodies Companies, Headquarters (States, Country)
4.3.2 United States Based Companies Therapeutic Monoclonal Antibodies Revenue, (2018-2023)
4.4 China Based Companies Therapeutic Monoclonal Antibodies Revenue and Market Share, 2018-2023
4.4.1 China Based Therapeutic Monoclonal Antibodies Companies, Company Headquarters (Province, Country)
4.4.2 China Based Companies Therapeutic Monoclonal Antibodies Revenue, (2018-2023)
4.5 Rest of World Based Therapeutic Monoclonal Antibodies Companies and Market Share, 2018-2023
4.5.1 Rest of World Based Therapeutic Monoclonal Antibodies Companies, Headquarters (States, Country)
4.5.2 Rest of World Based Companies Therapeutic Monoclonal Antibodies Revenue, (2018-2023)
5 MARKET ANALYSIS BY TYPE
5.1 World Therapeutic Monoclonal Antibodies Market Size Overview by Type: 2018 VS 2022 VS 2029
5.2 Segment Introduction by Type
5.2.1 Mouse-derived Antibodies
5.2.2 Chimeric Antibodies
5.2.3 Humanized Antibodies
5.3 Market Segment by Type
5.3.1 World Therapeutic Monoclonal Antibodies Market Size by Type (2018-2023)
5.3.2 World Therapeutic Monoclonal Antibodies Market Size by Type (2024-2029)
5.3.3 World Therapeutic Monoclonal Antibodies Market Size Market Share by Type (2018-2029)
6 MARKET ANALYSIS BY APPLICATION
6.1 World Therapeutic Monoclonal Antibodies Market Size Overview by Application: 2018 VS 2022 VS 2029
6.2 Segment Introduction by Application
6.2.1 Immune Diseases
6.2.2 Cancer
6.2.3 Other
6.3 Market Segment by Application
6.3.1 World Therapeutic Monoclonal Antibodies Market Size by Application (2018-2023)
6.3.2 World Therapeutic Monoclonal Antibodies Market Size by Application (2024-2029)
6.3.3 World Therapeutic Monoclonal Antibodies Market Size by Application (2018-2029)
7 COMPANY PROFILES
7.1 AbbVie
7.1.1 AbbVie Details
7.1.2 AbbVie Major Business
7.1.3 AbbVie Therapeutic Monoclonal Antibodies Product and Services
7.1.4 AbbVie Therapeutic Monoclonal Antibodies Revenue, Gross Margin and Market Share (2018-2023)
7.1.5 AbbVie Recent Developments/Updates
7.1.6 AbbVie Competitive Strengths & Weaknesses
7.2 Johnson & Johnson
7.2.1 Johnson & Johnson Details
7.2.2 Johnson & Johnson Major Business
7.2.3 Johnson & Johnson Therapeutic Monoclonal Antibodies Product and Services
7.2.4 Johnson & Johnson Therapeutic Monoclonal Antibodies Revenue, Gross Margin and Market Share (2018-2023)
7.2.5 Johnson & Johnson Recent Developments/Updates
7.2.6 Johnson & Johnson Competitive Strengths & Weaknesses
7.3 Novartis
7.3.1 Novartis Details
7.3.2 Novartis Major Business
7.3.3 Novartis Therapeutic Monoclonal Antibodies Product and Services
7.3.4 Novartis Therapeutic Monoclonal Antibodies Revenue, Gross Margin and Market Share (2018-2023)
7.3.5 Novartis Recent Developments/Updates
7.3.6 Novartis Competitive Strengths & Weaknesses
7.4 Gilead Sciences
7.4.1 Gilead Sciences Details
7.4.2 Gilead Sciences Major Business
7.4.3 Gilead Sciences Therapeutic Monoclonal Antibodies Product and Services
7.4.4 Gilead Sciences Therapeutic Monoclonal Antibodies Revenue, Gross Margin and Market Share (2018-2023)
7.4.5 Gilead Sciences Recent Developments/Updates
7.4.6 Gilead Sciences Competitive Strengths & Weaknesses
7.5 Roche
7.5.1 Roche Details
7.5.2 Roche Major Business
7.5.3 Roche Therapeutic Monoclonal Antibodies Product and Services
7.5.4 Roche Therapeutic Monoclonal Antibodies Revenue, Gross Margin and Market Share (2018-2023)
7.5.5 Roche Recent Developments/Updates
7.5.6 Roche Competitive Strengths & Weaknesses
7.6 Bristol-Myers Squibb
7.6.1 Bristol-Myers Squibb Details
7.6.2 Bristol-Myers Squibb Major Business
7.6.3 Bristol-Myers Squibb Therapeutic Monoclonal Antibodies Product and Services
7.6.4 Bristol-Myers Squibb Therapeutic Monoclonal Antibodies Revenue, Gross Margin and Market Share (2018-2023)
7.6.5 Bristol-Myers Squibb Recent Developments/Updates
7.6.6 Bristol-Myers Squibb Competitive Strengths & Weaknesses
7.7 Amgen
7.7.1 Amgen Details
7.7.2 Amgen Major Business
7.7.3 Amgen Therapeutic Monoclonal Antibodies Product and Services
7.7.4 Amgen Therapeutic Monoclonal Antibodies Revenue, Gross Margin and Market Share (2018-2023)
7.7.5 Amgen Recent Developments/Updates
7.7.6 Amgen Competitive Strengths & Weaknesses
7.8 AstraZeneca
7.8.1 AstraZeneca Details
7.8.2 AstraZeneca Major Business
7.8.3 AstraZeneca Therapeutic Monoclonal Antibodies Product and Services
7.8.4 AstraZeneca Therapeutic Monoclonal Antibodies Revenue, Gross Margin and Market Share (2018-2023)
7.8.5 AstraZeneca Recent Developments/Updates
7.8.6 AstraZeneca Competitive Strengths & Weaknesses
7.9 Merck & Co
7.9.1 Merck & Co Details
7.9.2 Merck & Co Major Business
7.9.3 Merck & Co Therapeutic Monoclonal Antibodies Product and Services
7.9.4 Merck & Co Therapeutic Monoclonal Antibodies Revenue, Gross Margin and Market Share (2018-2023)
7.9.5 Merck & Co Recent Developments/Updates
7.9.6 Merck & Co Competitive Strengths & Weaknesses
7.10 Takeda
7.10.1 Takeda Details
7.10.2 Takeda Major Business
7.10.3 Takeda Therapeutic Monoclonal Antibodies Product and Services
7.10.4 Takeda Therapeutic Monoclonal Antibodies Revenue, Gross Margin and Market Share (2018-2023)
7.10.5 Takeda Recent Developments/Updates
7.10.6 Takeda Competitive Strengths & Weaknesses
7.11 Merck KGaA
7.11.1 Merck KGaA Details
7.11.2 Merck KGaA Major Business
7.11.3 Merck KGaA Therapeutic Monoclonal Antibodies Product and Services
7.11.4 Merck KGaA Therapeutic Monoclonal Antibodies Revenue, Gross Margin and Market Share (2018-2023)
7.11.5 Merck KGaA Recent Developments/Updates
7.11.6 Merck KGaA Competitive Strengths & Weaknesses
7.12 Seagen
7.12.1 Seagen Details
7.12.2 Seagen Major Business
7.12.3 Seagen Therapeutic Monoclonal Antibodies Product and Services
7.12.4 Seagen Therapeutic Monoclonal Antibodies Revenue, Gross Margin and Market Share (2018-2023)
7.12.5 Seagen Recent Developments/Updates
7.12.6 Seagen Competitive Strengths & Weaknesses
7.13 Eli Lilly
7.13.1 Eli Lilly Details
7.13.2 Eli Lilly Major Business
7.13.3 Eli Lilly Therapeutic Monoclonal Antibodies Product and Services
7.13.4 Eli Lilly Therapeutic Monoclonal Antibodies Revenue, Gross Margin and Market Share (2018-2023)
7.13.5 Eli Lilly Recent Developments/Updates
7.13.6 Eli Lilly Competitive Strengths & Weaknesses
7.14 Ono Pharmaceutical
7.14.1 Ono Pharmaceutical Details
7.14.2 Ono Pharmaceutical Major Business
7.14.3 Ono Pharmaceutical Therapeutic Monoclonal Antibodies Product and Services
7.14.4 Ono Pharmaceutical Therapeutic Monoclonal Antibodies Revenue, Gross Margin and Market Share (2018-2023)
7.14.5 Ono Pharmaceutical Recent Developments/Updates
7.14.6 Ono Pharmaceutical Competitive Strengths & Weaknesses
7.15 Pfizer
7.15.1 Pfizer Details
7.15.2 Pfizer Major Business
7.15.3 Pfizer Therapeutic Monoclonal Antibodies Product and Services
7.15.4 Pfizer Therapeutic Monoclonal Antibodies Revenue, Gross Margin and Market Share (2018-2023)
7.15.5 Pfizer Recent Developments/Updates
7.15.6 Pfizer Competitive Strengths & Weaknesses
7.16 Regeneron
7.16.1 Regeneron Details
7.16.2 Regeneron Major Business
7.16.3 Regeneron Therapeutic Monoclonal Antibodies Product and Services
7.16.4 Regeneron Therapeutic Monoclonal Antibodies Revenue, Gross Margin and Market Share (2018-2023)
7.16.5 Regeneron Recent Developments/Updates
7.16.6 Regeneron Competitive Strengths & Weaknesses
7.17 Innovent
7.17.1 Innovent Details
7.17.2 Innovent Major Business
7.17.3 Innovent Therapeutic Monoclonal Antibodies Product and Services
7.17.4 Innovent Therapeutic Monoclonal Antibodies Revenue, Gross Margin and Market Share (2018-2023)
7.17.5 Innovent Recent Developments/Updates
7.17.6 Innovent Competitive Strengths & Weaknesses
7.18 Hengrui Medicine
7.18.1 Hengrui Medicine Details
7.18.2 Hengrui Medicine Major Business
7.18.3 Hengrui Medicine Therapeutic Monoclonal Antibodies Product and Services
7.18.4 Hengrui Medicine Therapeutic Monoclonal Antibodies Revenue, Gross Margin and Market Share (2018-2023)
7.18.5 Hengrui Medicine Recent Developments/Updates
7.18.6 Hengrui Medicine Competitive Strengths & Weaknesses
8 INDUSTRY CHAIN ANALYSIS
8.1 Therapeutic Monoclonal Antibodies Industry Chain
8.2 Therapeutic Monoclonal Antibodies Upstream Analysis
8.3 Therapeutic Monoclonal Antibodies Midstream Analysis
8.4 Therapeutic Monoclonal Antibodies Downstream Analysis
9 RESEARCH FINDINGS AND CONCLUSION
10 APPENDIX
10.1 Methodology
10.2 Research Process and Data Source
10.3 Disclaimer
LIST OF TABLES
Table 1. World Therapeutic Monoclonal Antibodies Revenue by Region (2018, 2022 and 2029) & (USD Million), (by Headquarter Location)
Table 2. World Therapeutic Monoclonal Antibodies Revenue by Region (2018-2023) & (USD Million), (by Headquarter Location)
Table 3. World Therapeutic Monoclonal Antibodies Revenue by Region (2024-2029) & (USD Million), (by Headquarter Location)
Table 4. World Therapeutic Monoclonal Antibodies Revenue Market Share by Region (2018-2023), (by Headquarter Location)
Table 5. World Therapeutic Monoclonal Antibodies Revenue Market Share by Region (2024-2029), (by Headquarter Location)
Table 6. Major Market Trends
Table 7. World Therapeutic Monoclonal Antibodies Consumption Value Growth Rate Forecast by Region (2018 & 2022 & 2029) & (USD Million)
Table 8. World Therapeutic Monoclonal Antibodies Consumption Value by Region (2018-2023) & (USD Million)
Table 9. World Therapeutic Monoclonal Antibodies Consumption Value Forecast by Region (2024-2029) & (USD Million)
Table 10. World Therapeutic Monoclonal Antibodies Revenue by Player (2018-2023) & (USD Million)
Table 11. Revenue Market Share of Key Therapeutic Monoclonal Antibodies Players in 2022
Table 12. World Therapeutic Monoclonal Antibodies Industry Rank of Major Player, Based on Revenue in 2022
Table 13. Global Therapeutic Monoclonal Antibodies Company Evaluation Quadrant
Table 14. Head Office of Key Therapeutic Monoclonal Antibodies Player
Table 15. Therapeutic Monoclonal Antibodies Market: Company Product Type Footprint
Table 16. Therapeutic Monoclonal Antibodies Market: Company Product Application Footprint
Table 17. Therapeutic Monoclonal Antibodies Mergers & Acquisitions Activity
Table 18. United States VS China Therapeutic Monoclonal Antibodies Market Size Comparison, (2018 & 2022 & 2029) & (USD Million)
Table 19. United States VS China Therapeutic Monoclonal Antibodies Consumption Value Comparison, (2018 & 2022 & 2029) & (USD Million)
Table 20. United States Based Therapeutic Monoclonal Antibodies Companies, Headquarters (States, Country)
Table 21. United States Based Companies Therapeutic Monoclonal Antibodies Revenue, (2018-2023) & (USD Million)
Table 22. United States Based Companies Therapeutic Monoclonal Antibodies Revenue Market Share (2018-2023)
Table 23. China Based Therapeutic Monoclonal Antibodies Companies, Headquarters (Province, Country)
Table 24. China Based Companies Therapeutic Monoclonal Antibodies Revenue, (2018-2023) & (USD Million)
Table 25. China Based Companies Therapeutic Monoclonal Antibodies Revenue Market Share (2018-2023)
Table 26. Rest of World Based Therapeutic Monoclonal Antibodies Companies, Headquarters (States, Country)
Table 27. Rest of World Based Companies Therapeutic Monoclonal Antibodies Revenue, (2018-2023) & (USD Million)
Table 28. Rest of World Based Companies Therapeutic Monoclonal Antibodies Revenue Market Share (2018-2023)
Table 29. World Therapeutic Monoclonal Antibodies Market Size by Type, (USD Million), 2018 & 2022 & 2029
Table 30. World Therapeutic Monoclonal Antibodies Market Size by Type (2018-2023) & (USD Million)
Table 31. World Therapeutic Monoclonal Antibodies Market Size by Type (2024-2029) & (USD Million)
Table 32. World Therapeutic Monoclonal Antibodies Market Size by Application, (USD Million), 2018 & 2022 & 2029
Table 33. World Therapeutic Monoclonal Antibodies Market Size by Application (2018-2023) & (USD Million)
Table 34. World Therapeutic Monoclonal Antibodies Market Size by Application (2024-2029) & (USD Million)
Table 35. AbbVie Basic Information, Area Served and Competitors
Table 36. AbbVie Major Business
Table 37. AbbVie Therapeutic Monoclonal Antibodies Product and Services
Table 38. AbbVie Therapeutic Monoclonal Antibodies Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 39. AbbVie Recent Developments/Updates
Table 40. AbbVie Competitive Strengths & Weaknesses
Table 41. Johnson & Johnson Basic Information, Area Served and Competitors
Table 42. Johnson & Johnson Major Business
Table 43. Johnson & Johnson Therapeutic Monoclonal Antibodies Product and Services
Table 44. Johnson & Johnson Therapeutic Monoclonal Antibodies Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 45. Johnson & Johnson Recent Developments/Updates
Table 46. Johnson & Johnson Competitive Strengths & Weaknesses
Table 47. Novartis Basic Information, Area Served and Competitors
Table 48. Novartis Major Business
Table 49. Novartis Therapeutic Monoclonal Antibodies Product and Services
Table 50. Novartis Therapeutic Monoclonal Antibodies Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 51. Novartis Recent Developments/Updates
Table 52. Novartis Competitive Strengths & Weaknesses
Table 53. Gilead Sciences Basic Information, Area Served and Competitors
Table 54. Gilead Sciences Major Business
Table 55. Gilead Sciences Therapeutic Monoclonal Antibodies Product and Services
Table 56. Gilead Sciences Therapeutic Monoclonal Antibodies Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 57. Gilead Sciences Recent Developments/Updates
Table 58. Gilead Sciences Competitive Strengths & Weaknesses
Table 59. Roche Basic Information, Area Served and Competitors
Table 60. Roche Major Business
Table 61. Roche Therapeutic Monoclonal Antibodies Product and Services
Table 62. Roche Therapeutic Monoclonal Antibodies Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 63. Roche Recent Developments/Updates
Table 64. Roche Competitive Strengths & Weaknesses
Table 65. Bristol-Myers Squibb Basic Information, Area Served and Competitors
Table 66. Bristol-Myers Squibb Major Business
Table 67. Bristol-Myers Squibb Therapeutic Monoclonal Antibodies Product and Services
Table 68. Bristol-Myers Squibb Therapeutic Monoclonal Antibodies Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 69. Bristol-Myers Squibb Recent Developments/Updates
Table 70. Bristol-Myers Squibb Competitive Strengths & Weaknesses
Table 71. Amgen Basic Information, Area Served and Competitors
Table 72. Amgen Major Business
Table 73. Amgen Therapeutic Monoclonal Antibodies Product and Services
Table 74. Amgen Therapeutic Monoclonal Antibodies Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 75. Amgen Recent Developments/Updates
Table 76. Amgen Competitive Strengths & Weaknesses
Table 77. AstraZeneca Basic Information, Area Served and Competitors
Table 78. AstraZeneca Major Business
Table 79. AstraZeneca Therapeutic Monoclonal Antibodies Product and Services
Table 80. AstraZeneca Therapeutic Monoclonal Antibodies Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 81. AstraZeneca Recent Developments/Updates
Table 82. AstraZeneca Competitive Strengths & Weaknesses
Table 83. Merck & Co Basic Information, Area Served and Competitors
Table 84. Merck & Co Major Business
Table 85. Merck & Co Therapeutic Monoclonal Antibodies Product and Services
Table 86. Merck & Co Therapeutic Monoclonal Antibodies Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 87. Merck & Co Recent Developments/Updates
Table 88. Merck & Co Competitive Strengths & Weaknesses
Table 89. Takeda Basic Information, Area Served and Competitors
Table 90. Takeda Major Business
Table 91. Takeda Therapeutic Monoclonal Antibodies Product and Services
Table 92. Takeda Therapeutic Monoclonal Antibodies Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 93. Takeda Recent Developments/Updates
Table 94. Takeda Competitive Strengths & Weaknesses
Table 95. Merck KGaA Basic Information, Area Served and Competitors
Table 96. Merck KGaA Major Business
Table 97. Merck KGaA Therapeutic Monoclonal Antibodies Product and Services
Table 98. Merck KGaA Therapeutic Monoclonal Antibodies Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 99. Merck KGaA Recent Developments/Updates
Table 100. Merck KGaA Competitive Strengths & Weaknesses
Table 101. Seagen Basic Information, Area Served and Competitors
Table 102. Seagen Major Business
Table 103. Seagen Therapeutic Monoclonal Antibodies Product and Services
Table 104. Seagen Therapeutic Monoclonal Antibodies Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 105. Seagen Recent Developments/Updates
Table 106. Seagen Competitive Strengths & Weaknesses
Table 107. Eli Lilly Basic Information, Area Served and Competitors
Table 108. Eli Lilly Major Business
Table 109. Eli Lilly Therapeutic Monoclonal Antibodies Product and Services
Table 110. Eli Lilly Therapeutic Monoclonal Antibodies Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 111. Eli Lilly Recent Developments/Updates
Table 112. Eli Lilly Competitive Strengths & Weaknesses
Table 113. Ono Pharmaceutical Basic Information, Area Served and Competitors
Table 114. Ono Pharmaceutical Major Business
Table 115. Ono Pharmaceutical Therapeutic Monoclonal Antibodies Product and Services
Table 116. Ono Pharmaceutical Therapeutic Monoclonal Antibodies Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 117. Ono Pharmaceutical Recent Developments/Updates
Table 118. Ono Pharmaceutical Competitive Strengths & Weaknesses
Table 119. Pfizer Basic Information, Area Served and Competitors
Table 120. Pfizer Major Business
Table 121. Pfizer Therapeutic Monoclonal Antibodies Product and Services
Table 122. Pfizer Therapeutic Monoclonal Antibodies Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 123. Pfizer Recent Developments/Updates
Table 124. Pfizer Competitive Strengths & Weaknesses
Table 125. Regeneron Basic Information, Area Served and Competitors
Table 126. Regeneron Major Business
Table 127. Regeneron Therapeutic Monoclonal Antibodies Product and Services
Table 128. Regeneron Therapeutic Monoclonal Antibodies Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 129. Regeneron Recent Developments/Updates
Table 130. Regeneron Competitive Strengths & Weaknesses
Table 131. Innovent Basic Information, Area Served and Competitors
Table 132. Innovent Major Business
Table 133. Innovent Therapeutic Monoclonal Antibodies Product and Services
Table 134. Innovent Therapeutic Monoclonal Antibodies Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 135. Innovent Recent Developments/Updates
Table 136. Hengrui Medicine Basic Information, Area Served and Competitors
Table 137. Hengrui Medicine Major Business
Table 138. Hengrui Medicine Therapeutic Monoclonal Antibodies Product and Services
Table 139. Hengrui Medicine Therapeutic Monoclonal Antibodies Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 140. Global Key Players of Therapeutic Monoclonal Antibodies Upstream (Raw Materials)
Table 141. Therapeutic Monoclonal Antibodies Typical Customers
LIST OF FIGURE
Figure 1. Therapeutic Monoclonal Antibodies Picture
Figure 2. World Therapeutic Monoclonal Antibodies Total Market Size: 2018 & 2022 & 2029, (USD Million)
Figure 3. World Therapeutic Monoclonal Antibodies Total Market Size (2018-2029) & (USD Million)
Figure 4. World Therapeutic Monoclonal Antibodies Revenue Market Share by Region (2018, 2022 and 2029) & (USD Million) , (by Headquarter Location)
Figure 5. World Therapeutic Monoclonal Antibodies Revenue Market Share by Region (2018-2029), (by Headquarter Location)
Figure 6. United States Based Company Therapeutic Monoclonal Antibodies Revenue (2018-2029) & (USD Million)
Figure 7. China Based Company Therapeutic Monoclonal Antibodies Revenue (2018-2029) & (USD Million)
Figure 8. Europe Based Company Therapeutic Monoclonal Antibodies Revenue (2018-2029) & (USD Million)
Figure 9. Japan Based Company Therapeutic Monoclonal Antibodies Revenue (2018-2029) & (USD Million)
Figure 10. South Korea Based Company Therapeutic Monoclonal Antibodies Revenue (2018-2029) & (USD Million)
Figure 11. ASEAN Based Company Therapeutic Monoclonal Antibodies Revenue (2018-2029) & (USD Million)
Figure 12. India Based Company Therapeutic Monoclonal Antibodies Revenue (2018-2029) & (USD Million)
Figure 13. Therapeutic Monoclonal Antibodies Market Drivers
Figure 14. Factors Affecting Demand
Figure 15. World Therapeutic Monoclonal Antibodies Consumption Value (2018-2029) & (USD Million)
Figure 16. World Therapeutic Monoclonal Antibodies Consumption Value Market Share by Region (2018-2029)
Figure 17. United States Therapeutic Monoclonal Antibodies Consumption Value (2018-2029) & (USD Million)
Figure 18. China Therapeutic Monoclonal Antibodies Consumption Value (2018-2029) & (USD Million)
Figure 19. Europe Therapeutic Monoclonal Antibodies Consumption Value (2018-2029) & (USD Million)
Figure 20. Japan Therapeutic Monoclonal Antibodies Consumption Value (2018-2029) & (USD Million)
Figure 21. South Korea Therapeutic Monoclonal Antibodies Consumption Value (2018-2029) & (USD Million)
Figure 22. ASEAN Therapeutic Monoclonal Antibodies Consumption Value (2018-2029) & (USD Million)
Figure 23. India Therapeutic Monoclonal Antibodies Consumption Value (2018-2029) & (USD Million)
Figure 24. Producer Shipments of Therapeutic Monoclonal Antibodies by Player Revenue ($MM) and Market Share (%): 2022
Figure 25. Global Four-firm Concentration Ratios (CR4) for Therapeutic Monoclonal Antibodies Markets in 2022
Figure 26. Global Four-firm Concentration Ratios (CR8) for Therapeutic Monoclonal Antibodies Markets in 2022
Figure 27. United States VS China: Therapeutic Monoclonal Antibodies Revenue Market Share Comparison (2018 & 2022 & 2029)
Figure 28. United States VS China: Therapeutic Monoclonal Antibodies Consumption Value Market Share Comparison (2018 & 2022 & 2029)
Figure 29. World Therapeutic Monoclonal Antibodies Market Size by Type, (USD Million), 2018 & 2022 & 2029
Figure 30. World Therapeutic Monoclonal Antibodies Market Size Market Share by Type in 2022
Figure 31. Mouse-derived Antibodies
Figure 32. Chimeric Antibodies
Figure 33. Humanized Antibodies
Figure 34. World Therapeutic Monoclonal Antibodies Market Size Market Share by Type (2018-2029)
Figure 35. World Therapeutic Monoclonal Antibodies Market Size by Application, (USD Million), 2018 & 2022 & 2029
Figure 36. World Therapeutic Monoclonal Antibodies Market Size Market Share by Application in 2022
Figure 37. Immune Diseases
Figure 38. Cancer
Figure 39. Other
Figure 40. Therapeutic Monoclonal Antibodies Industrial Chain
Figure 41. Methodology
Figure 42. Research Process and Data Source
Table 1. World Therapeutic Monoclonal Antibodies Revenue by Region (2018, 2022 and 2029) & (USD Million), (by Headquarter Location)
Table 2. World Therapeutic Monoclonal Antibodies Revenue by Region (2018-2023) & (USD Million), (by Headquarter Location)
Table 3. World Therapeutic Monoclonal Antibodies Revenue by Region (2024-2029) & (USD Million), (by Headquarter Location)
Table 4. World Therapeutic Monoclonal Antibodies Revenue Market Share by Region (2018-2023), (by Headquarter Location)
Table 5. World Therapeutic Monoclonal Antibodies Revenue Market Share by Region (2024-2029), (by Headquarter Location)
Table 6. Major Market Trends
Table 7. World Therapeutic Monoclonal Antibodies Consumption Value Growth Rate Forecast by Region (2018 & 2022 & 2029) & (USD Million)
Table 8. World Therapeutic Monoclonal Antibodies Consumption Value by Region (2018-2023) & (USD Million)
Table 9. World Therapeutic Monoclonal Antibodies Consumption Value Forecast by Region (2024-2029) & (USD Million)
Table 10. World Therapeutic Monoclonal Antibodies Revenue by Player (2018-2023) & (USD Million)
Table 11. Revenue Market Share of Key Therapeutic Monoclonal Antibodies Players in 2022
Table 12. World Therapeutic Monoclonal Antibodies Industry Rank of Major Player, Based on Revenue in 2022
Table 13. Global Therapeutic Monoclonal Antibodies Company Evaluation Quadrant
Table 14. Head Office of Key Therapeutic Monoclonal Antibodies Player
Table 15. Therapeutic Monoclonal Antibodies Market: Company Product Type Footprint
Table 16. Therapeutic Monoclonal Antibodies Market: Company Product Application Footprint
Table 17. Therapeutic Monoclonal Antibodies Mergers & Acquisitions Activity
Table 18. United States VS China Therapeutic Monoclonal Antibodies Market Size Comparison, (2018 & 2022 & 2029) & (USD Million)
Table 19. United States VS China Therapeutic Monoclonal Antibodies Consumption Value Comparison, (2018 & 2022 & 2029) & (USD Million)
Table 20. United States Based Therapeutic Monoclonal Antibodies Companies, Headquarters (States, Country)
Table 21. United States Based Companies Therapeutic Monoclonal Antibodies Revenue, (2018-2023) & (USD Million)
Table 22. United States Based Companies Therapeutic Monoclonal Antibodies Revenue Market Share (2018-2023)
Table 23. China Based Therapeutic Monoclonal Antibodies Companies, Headquarters (Province, Country)
Table 24. China Based Companies Therapeutic Monoclonal Antibodies Revenue, (2018-2023) & (USD Million)
Table 25. China Based Companies Therapeutic Monoclonal Antibodies Revenue Market Share (2018-2023)
Table 26. Rest of World Based Therapeutic Monoclonal Antibodies Companies, Headquarters (States, Country)
Table 27. Rest of World Based Companies Therapeutic Monoclonal Antibodies Revenue, (2018-2023) & (USD Million)
Table 28. Rest of World Based Companies Therapeutic Monoclonal Antibodies Revenue Market Share (2018-2023)
Table 29. World Therapeutic Monoclonal Antibodies Market Size by Type, (USD Million), 2018 & 2022 & 2029
Table 30. World Therapeutic Monoclonal Antibodies Market Size by Type (2018-2023) & (USD Million)
Table 31. World Therapeutic Monoclonal Antibodies Market Size by Type (2024-2029) & (USD Million)
Table 32. World Therapeutic Monoclonal Antibodies Market Size by Application, (USD Million), 2018 & 2022 & 2029
Table 33. World Therapeutic Monoclonal Antibodies Market Size by Application (2018-2023) & (USD Million)
Table 34. World Therapeutic Monoclonal Antibodies Market Size by Application (2024-2029) & (USD Million)
Table 35. AbbVie Basic Information, Area Served and Competitors
Table 36. AbbVie Major Business
Table 37. AbbVie Therapeutic Monoclonal Antibodies Product and Services
Table 38. AbbVie Therapeutic Monoclonal Antibodies Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 39. AbbVie Recent Developments/Updates
Table 40. AbbVie Competitive Strengths & Weaknesses
Table 41. Johnson & Johnson Basic Information, Area Served and Competitors
Table 42. Johnson & Johnson Major Business
Table 43. Johnson & Johnson Therapeutic Monoclonal Antibodies Product and Services
Table 44. Johnson & Johnson Therapeutic Monoclonal Antibodies Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 45. Johnson & Johnson Recent Developments/Updates
Table 46. Johnson & Johnson Competitive Strengths & Weaknesses
Table 47. Novartis Basic Information, Area Served and Competitors
Table 48. Novartis Major Business
Table 49. Novartis Therapeutic Monoclonal Antibodies Product and Services
Table 50. Novartis Therapeutic Monoclonal Antibodies Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 51. Novartis Recent Developments/Updates
Table 52. Novartis Competitive Strengths & Weaknesses
Table 53. Gilead Sciences Basic Information, Area Served and Competitors
Table 54. Gilead Sciences Major Business
Table 55. Gilead Sciences Therapeutic Monoclonal Antibodies Product and Services
Table 56. Gilead Sciences Therapeutic Monoclonal Antibodies Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 57. Gilead Sciences Recent Developments/Updates
Table 58. Gilead Sciences Competitive Strengths & Weaknesses
Table 59. Roche Basic Information, Area Served and Competitors
Table 60. Roche Major Business
Table 61. Roche Therapeutic Monoclonal Antibodies Product and Services
Table 62. Roche Therapeutic Monoclonal Antibodies Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 63. Roche Recent Developments/Updates
Table 64. Roche Competitive Strengths & Weaknesses
Table 65. Bristol-Myers Squibb Basic Information, Area Served and Competitors
Table 66. Bristol-Myers Squibb Major Business
Table 67. Bristol-Myers Squibb Therapeutic Monoclonal Antibodies Product and Services
Table 68. Bristol-Myers Squibb Therapeutic Monoclonal Antibodies Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 69. Bristol-Myers Squibb Recent Developments/Updates
Table 70. Bristol-Myers Squibb Competitive Strengths & Weaknesses
Table 71. Amgen Basic Information, Area Served and Competitors
Table 72. Amgen Major Business
Table 73. Amgen Therapeutic Monoclonal Antibodies Product and Services
Table 74. Amgen Therapeutic Monoclonal Antibodies Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 75. Amgen Recent Developments/Updates
Table 76. Amgen Competitive Strengths & Weaknesses
Table 77. AstraZeneca Basic Information, Area Served and Competitors
Table 78. AstraZeneca Major Business
Table 79. AstraZeneca Therapeutic Monoclonal Antibodies Product and Services
Table 80. AstraZeneca Therapeutic Monoclonal Antibodies Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 81. AstraZeneca Recent Developments/Updates
Table 82. AstraZeneca Competitive Strengths & Weaknesses
Table 83. Merck & Co Basic Information, Area Served and Competitors
Table 84. Merck & Co Major Business
Table 85. Merck & Co Therapeutic Monoclonal Antibodies Product and Services
Table 86. Merck & Co Therapeutic Monoclonal Antibodies Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 87. Merck & Co Recent Developments/Updates
Table 88. Merck & Co Competitive Strengths & Weaknesses
Table 89. Takeda Basic Information, Area Served and Competitors
Table 90. Takeda Major Business
Table 91. Takeda Therapeutic Monoclonal Antibodies Product and Services
Table 92. Takeda Therapeutic Monoclonal Antibodies Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 93. Takeda Recent Developments/Updates
Table 94. Takeda Competitive Strengths & Weaknesses
Table 95. Merck KGaA Basic Information, Area Served and Competitors
Table 96. Merck KGaA Major Business
Table 97. Merck KGaA Therapeutic Monoclonal Antibodies Product and Services
Table 98. Merck KGaA Therapeutic Monoclonal Antibodies Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 99. Merck KGaA Recent Developments/Updates
Table 100. Merck KGaA Competitive Strengths & Weaknesses
Table 101. Seagen Basic Information, Area Served and Competitors
Table 102. Seagen Major Business
Table 103. Seagen Therapeutic Monoclonal Antibodies Product and Services
Table 104. Seagen Therapeutic Monoclonal Antibodies Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 105. Seagen Recent Developments/Updates
Table 106. Seagen Competitive Strengths & Weaknesses
Table 107. Eli Lilly Basic Information, Area Served and Competitors
Table 108. Eli Lilly Major Business
Table 109. Eli Lilly Therapeutic Monoclonal Antibodies Product and Services
Table 110. Eli Lilly Therapeutic Monoclonal Antibodies Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 111. Eli Lilly Recent Developments/Updates
Table 112. Eli Lilly Competitive Strengths & Weaknesses
Table 113. Ono Pharmaceutical Basic Information, Area Served and Competitors
Table 114. Ono Pharmaceutical Major Business
Table 115. Ono Pharmaceutical Therapeutic Monoclonal Antibodies Product and Services
Table 116. Ono Pharmaceutical Therapeutic Monoclonal Antibodies Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 117. Ono Pharmaceutical Recent Developments/Updates
Table 118. Ono Pharmaceutical Competitive Strengths & Weaknesses
Table 119. Pfizer Basic Information, Area Served and Competitors
Table 120. Pfizer Major Business
Table 121. Pfizer Therapeutic Monoclonal Antibodies Product and Services
Table 122. Pfizer Therapeutic Monoclonal Antibodies Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 123. Pfizer Recent Developments/Updates
Table 124. Pfizer Competitive Strengths & Weaknesses
Table 125. Regeneron Basic Information, Area Served and Competitors
Table 126. Regeneron Major Business
Table 127. Regeneron Therapeutic Monoclonal Antibodies Product and Services
Table 128. Regeneron Therapeutic Monoclonal Antibodies Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 129. Regeneron Recent Developments/Updates
Table 130. Regeneron Competitive Strengths & Weaknesses
Table 131. Innovent Basic Information, Area Served and Competitors
Table 132. Innovent Major Business
Table 133. Innovent Therapeutic Monoclonal Antibodies Product and Services
Table 134. Innovent Therapeutic Monoclonal Antibodies Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 135. Innovent Recent Developments/Updates
Table 136. Hengrui Medicine Basic Information, Area Served and Competitors
Table 137. Hengrui Medicine Major Business
Table 138. Hengrui Medicine Therapeutic Monoclonal Antibodies Product and Services
Table 139. Hengrui Medicine Therapeutic Monoclonal Antibodies Revenue, Gross Margin and Market Share (2018-2023) & (USD Million)
Table 140. Global Key Players of Therapeutic Monoclonal Antibodies Upstream (Raw Materials)
Table 141. Therapeutic Monoclonal Antibodies Typical Customers
LIST OF FIGURE
Figure 1. Therapeutic Monoclonal Antibodies Picture
Figure 2. World Therapeutic Monoclonal Antibodies Total Market Size: 2018 & 2022 & 2029, (USD Million)
Figure 3. World Therapeutic Monoclonal Antibodies Total Market Size (2018-2029) & (USD Million)
Figure 4. World Therapeutic Monoclonal Antibodies Revenue Market Share by Region (2018, 2022 and 2029) & (USD Million) , (by Headquarter Location)
Figure 5. World Therapeutic Monoclonal Antibodies Revenue Market Share by Region (2018-2029), (by Headquarter Location)
Figure 6. United States Based Company Therapeutic Monoclonal Antibodies Revenue (2018-2029) & (USD Million)
Figure 7. China Based Company Therapeutic Monoclonal Antibodies Revenue (2018-2029) & (USD Million)
Figure 8. Europe Based Company Therapeutic Monoclonal Antibodies Revenue (2018-2029) & (USD Million)
Figure 9. Japan Based Company Therapeutic Monoclonal Antibodies Revenue (2018-2029) & (USD Million)
Figure 10. South Korea Based Company Therapeutic Monoclonal Antibodies Revenue (2018-2029) & (USD Million)
Figure 11. ASEAN Based Company Therapeutic Monoclonal Antibodies Revenue (2018-2029) & (USD Million)
Figure 12. India Based Company Therapeutic Monoclonal Antibodies Revenue (2018-2029) & (USD Million)
Figure 13. Therapeutic Monoclonal Antibodies Market Drivers
Figure 14. Factors Affecting Demand
Figure 15. World Therapeutic Monoclonal Antibodies Consumption Value (2018-2029) & (USD Million)
Figure 16. World Therapeutic Monoclonal Antibodies Consumption Value Market Share by Region (2018-2029)
Figure 17. United States Therapeutic Monoclonal Antibodies Consumption Value (2018-2029) & (USD Million)
Figure 18. China Therapeutic Monoclonal Antibodies Consumption Value (2018-2029) & (USD Million)
Figure 19. Europe Therapeutic Monoclonal Antibodies Consumption Value (2018-2029) & (USD Million)
Figure 20. Japan Therapeutic Monoclonal Antibodies Consumption Value (2018-2029) & (USD Million)
Figure 21. South Korea Therapeutic Monoclonal Antibodies Consumption Value (2018-2029) & (USD Million)
Figure 22. ASEAN Therapeutic Monoclonal Antibodies Consumption Value (2018-2029) & (USD Million)
Figure 23. India Therapeutic Monoclonal Antibodies Consumption Value (2018-2029) & (USD Million)
Figure 24. Producer Shipments of Therapeutic Monoclonal Antibodies by Player Revenue ($MM) and Market Share (%): 2022
Figure 25. Global Four-firm Concentration Ratios (CR4) for Therapeutic Monoclonal Antibodies Markets in 2022
Figure 26. Global Four-firm Concentration Ratios (CR8) for Therapeutic Monoclonal Antibodies Markets in 2022
Figure 27. United States VS China: Therapeutic Monoclonal Antibodies Revenue Market Share Comparison (2018 & 2022 & 2029)
Figure 28. United States VS China: Therapeutic Monoclonal Antibodies Consumption Value Market Share Comparison (2018 & 2022 & 2029)
Figure 29. World Therapeutic Monoclonal Antibodies Market Size by Type, (USD Million), 2018 & 2022 & 2029
Figure 30. World Therapeutic Monoclonal Antibodies Market Size Market Share by Type in 2022
Figure 31. Mouse-derived Antibodies
Figure 32. Chimeric Antibodies
Figure 33. Humanized Antibodies
Figure 34. World Therapeutic Monoclonal Antibodies Market Size Market Share by Type (2018-2029)
Figure 35. World Therapeutic Monoclonal Antibodies Market Size by Application, (USD Million), 2018 & 2022 & 2029
Figure 36. World Therapeutic Monoclonal Antibodies Market Size Market Share by Application in 2022
Figure 37. Immune Diseases
Figure 38. Cancer
Figure 39. Other
Figure 40. Therapeutic Monoclonal Antibodies Industrial Chain
Figure 41. Methodology
Figure 42. Research Process and Data Source
